

Amendments to Claims

1-26. **(Canceled)**

27. **(Currently Amended)** A molecular conjugate comprising a human monoclonal antibody that binds to the human macrophage mannose receptor, linked to an antigen.

28. **(Original)** The molecular conjugate of claim 27, wherein the antigen comprises a component of a pathogen.

29. **(Original)** The molecular conjugate of claim 27, wherein the antigen comprises a tumor antigen or an autoantigen.

30. **(Original)** The molecular conjugate of claim 27, wherein the antibody portion of the conjugate comprises an antibody fragment or a single chain antibody.

31. **(Currently Amended)** A molecular conjugate comprising a human monoclonal antibody that binds to human dendritic cells, linked to an antigen, wherein the antibody comprises heavy chain and light chain variable regions which comprise the amino acid sequences shown in SEQ ID NO:2 and SEQ ID NO:4, respectively.

32. **(Currently Amended)** The molecular conjugate of claim 27 or 31, wherein the antigen is a melanoma antigen.

33. **(Currently Amended)** A molecular conjugate comprising a human monoclonal antibody that binds to the human macrophage mannose receptor, linked to Pmel-17 antigen.

34. **(Previously Presented)** The molecular conjugate of claim 33, wherein the antibody comprises heavy chain and light chain variable regions which comprise the amino acid sequences shown in SEQ ID NO:2 and SEQ ID NO:4, respectively.

35. **(Original)** The molecular conjugate of claim 33, encoded by the nucleotide sequence shown in SEQ ID NO:8.

36-37. **(Canceled)**

38. **(Previously Presented)** A composition comprising a molecular conjugate according to claim 27, 31 or 33 and a pharmaceutically acceptable carrier.

39. **(Original)** The composition of claim 38 further comprising an adjuvant.

40-41. **(Canceled)**

42. **(Withdrawn)** A method for targeting an antigen to a dendritic cell in a subject comprising administering to the subject the composition according to claim 38.

43. **(Withdrawn)** A method of inducing or enhancing an immune response against an antigen in a subject comprising administering to the subject the composition according to claim 38.

44. **(Withdrawn)** The method of claim 43, wherein the immune response comprises presentation of the antigen as a component of an MHC-I or MHC-II conjugate.

45. **(Withdrawn)** A method of immunizing a subject comprising administering to the subject the composition according to claim 38.

46. **(Withdrawn)** The method of claim 45, wherein the composition is administered in an amount sufficient to induce cytokine release by dendritic cells.

47-50. **(Canceled)**

51. **(Previously Presented)** The molecular conjugate of claim 27, wherein the receptor comprises the amino acid sequence shown in SEQ ID NO:7.

52. **(Previously Presented)** The molecular conjugate of claim 30, produced as a recombinant fusion protein or a chemical conjugate.

53. **(New)** The molecular conjugate of claim 32, wherein the melanoma antigen is selected from the group consisting of MART1, melan-A, NY-ESO-1, MAGE-1, MAGE-3, and high molecular weight-melanoma associated antigen (HMW-MAA).

54. **(New)** The molecular conjugate of claim 53, wherein the melanoma-specific antigen is high molecular weight-melanoma associated antigen (HMW-MAA).

55. **(New)** A composition comprising the molecular conjugate of claim 53 and a pharmaceutically acceptable carrier.

56. **(New)** A composition comprising the molecular conjugate of claim 54 and a pharmaceutically acceptable carrier.